Genentech to Present 46 Hematology Abstracts at ASH 2025, Including New AAV Gene Therapy and Oncology Data

South San Francisco, CA — November 3, 2025 — Biotech leader Genentech announced that it will present 46 abstracts, including 12 oral presentations, from its hematology portfolio at the upcoming ASH 2025 Annual Meeting in Orlando, Florida, scheduled for December 6-9, 2025. The submissions span across bleeding disorders, lymphomas, multiple myeloma and will feature new data from its AAV-based gene therapy pipeline.

Within the bleeding disorders track, Genentech plans to share post-marketing results for its approved therapy Hemlibra, positive Phase I/II results for next-generation investigational bispecific antibody NXT007, and preclinical data for SPK-8011QQ — a next-gen AAV gene therapy candidate showing superior hemostatic potency compared with prior vector versions in ex vivo and in vivo models. SPK-8011QQ is slated to enter Phase IIb clinical trials in 2026.

Photo by Julia Koblitz on Unsplash

For oncology and hematologic malignancies, the abstracts include long-term survival and subgroup analyses from combination regimens like Columvi + GemOx in relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), as well as biomarker and efficacy data from Cevostamab use in relapsed/refractory multiple myeloma (RRMM). These results will update the global community on efficacy, safety and durability of Genentech’s cutting-edge therapies in blood cancers.

Levi Garraway, M.D., Ph.D., Global Product Development Head and Chief Medical Officer at Genentech, commented: “The data we will present at ASH 2025 underscore our commitment to driving innovation across hematology and reflect meaningful progress towards improved treatment of multiple blood disorders.”

Photo by Testalize.me on Unsplash

The upcoming data release is viewed as a key milestone in Genentech’s dual-track strategy combining traditional biologics, antibody therapeutics, and advanced gene/CAR-T therapies. Given the accelerating interest and investment in AAV-vector gene therapies and bispecific immunotherapies within hematology and oncology, the forthcoming presentations are expected to influence clinical practices, guide future R&D, and shape industry trends.

Source: Genentech press release, Genentech to Present New Data From Its Broad and Innovative Hematology Portfolio at ASH 2025, November 3, 2025.